Infectious Disease Immunoassay Market Size Forecasted to Reach USD 8.87 Billion by 2035 Driven by AI Integration and Rapid Diagnostic Innovations

According to Precedence Research, the global infectious disease immunoassay market size was estimated at USD 2.88 billion in 2025 and is forecasted to reach around USD 8.87 billion by 2035, growing at a robust CAGR of 11.90%.
Immunoassays have become indispensable tools across hospitals, diagnostic laboratories, and public health systems, enabling accurate detection of viral, bacterial, and parasitic infections. With growing global health challenges and a shift toward decentralized healthcare, the market is poised for sustained expansion.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8237

Market Size and Forecasts

🔹 Market size in 2025: USD 2.88 Billion
🔹 Market size in 2026: USD 3.22 Billion
🔹 Market size by 2035: USD 8.87 Billion
🔹 CAGR: 11.90% (2026-2035)
🔹 Forecast period: 2026-2035
🔹 Base year: 2025

How is Artificial Intelligence Transforming Infectious Disease Immunoassays?

Artificial intelligence (AI) is playing a transformative role in enhancing the accuracy and efficiency of immunoassay diagnostics. AI-powered algorithms are being integrated into diagnostic platforms to enable faster data interpretation, reduce human error, and support clinical decision-making. This is especially crucial in high-throughput laboratories handling large volumes of patient samples.

Moreover, AI is enabling predictive diagnostics by analyzing patterns in infectious disease outbreaks and patient data. This allows healthcare providers to anticipate disease spread and implement early intervention strategies. The convergence of AI with immunoassay platforms is expected to revolutionize disease detection and surveillance in the coming years.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/infectious-disease-immunoassay-market

Infectious Disease Immunoassay Market Key Growth Drivers

🔸 Rising Burden of Infectious Diseases: Increasing cases of respiratory infections, hepatitis, HIV, and emerging pathogens are driving demand for accurate diagnostics.
🔸 Expansion of Diagnostic Infrastructure: Growth in diagnostic centers, laboratories, and home-based testing is accelerating market adoption.
🔸 Shift Toward Rapid Testing Solutions: Demand for portable, easy-to-use, and quick-result diagnostic kits is boosting immunoassay usage globally.
🔸 Technological Advancements: Integration of AI, biosensors, and microfluidics is enhancing diagnostic precision and efficiency.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Infectious Disease Immunoassay Market Opportunities

🔸 Integration with Nanotechnology and Microfluidics: These technologies offer faster analysis, higher sensitivity, and reduced sample requirements.
🔸 Growth in Emerging Markets: Expanding healthcare infrastructure in Asia-Pacific and Latin America presents significant opportunities.
🔸 Personalized and Preventive Healthcare: Increasing focus on early detection and preventive care is boosting demand for immunoassays.
🔸 Telemedicine and Remote Monitoring: Digital health integration is opening new avenues for at-home diagnostics.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8237

Infectious Disease Immunoassay Market Trends

🔸 AI-Powered Diagnostics: Artificial intelligence is revolutionizing disease detection through advanced data analysis, pattern recognition, and real-time decision-making. AI-enhanced immunoassays improve diagnostic accuracy, speed, and outbreak monitoring.
🔸 Rise of Point-of-Care (POC) Testing: Rapid, decentralized diagnostics are transforming healthcare delivery. Technologies like lateral flow immunoassays (LFIA) and CRISPR-based platforms provide fast, cost-effective results, often within 30 minutes.
🔸 Advanced In Vitro Models: The adoption of 3D models such as organoids and organ-on-chip systems is improving disease modeling, enabling better understanding of host-pathogen interactions and accelerating therapeutic development.
🔸 Multiplex and High-Throughput Testing: Multiplex immunoassays allow simultaneous detection of multiple biomarkers, enhancing efficiency and providing comprehensive diagnostic insights.
🔸 Digital and Cloud Integration: Smart diagnostic kits connected to smartphones and cloud platforms are enabling remote monitoring, telemedicine integration, and improved patient outcomes.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8237

Infectious Disease Immunoassay Market Regional Insights

North America held the largest market share of 34.8% in 2025, driven by advanced laboratory automation, strong government initiatives, and widespread adoption of multiplex testing. The region benefits from a favorable regulatory environment and significant investments in infectious disease surveillance.

Asia-Pacific is expected to witness the fastest growth due to rapid healthcare modernization, increasing awareness of preventive healthcare, and expansion of diagnostic infrastructure. Countries like India and China are investing heavily in disease control systems and laboratory networks.

Infectious Disease Immunoassay Market Segmentation

🔹 Product Type Insights

Reagents and kits held the largest share of 56.8% in 2025, driven by their essential role in every immunoassay test. These consumables including antibodies, substrates, and conjugates are required for routine diagnostics and outbreak monitoring, creating consistent recurring demand.

Software and data management solutions are projected to grow at the fastest rate, with a CAGR of 12.3%. Their growth is fueled by the increasing adoption of laboratory information management systems (LIMS), which improve data accuracy, workflow efficiency, and centralized management of diagnostic data.

🔹 Technology Insights

Chemiluminescent immunoassay (CLIA) accounted for the largest share of 34.6% in 2025. Its high sensitivity and ability to detect low levels of biomarkers make it a preferred choice for accurate disease monitoring and progression analysis.

Multiplex immunoassays are expected to grow at the fastest pace (CAGR of 13.4%). These platforms allow simultaneous detection of multiple analytes, offering high-throughput and comprehensive diagnostic capabilities through technologies like microfluidics and bead-based systems.

🔹 Test Type Insights

Antibody detection immunoassays dominated the market in 2025 due to their critical role in disease diagnosis, immunity assessment, and vaccine monitoring. They are widely used for screening chronic infections such as HIV.

Combined antigen and antibody immunoassays are expected to grow the fastest (CAGR of 10.8%). These tests enable early detection of infections and support timely clinical intervention, often within a single visit.

🔹 Disease Type Insights

Hepatitis immunoassays led the market with a 23.8% share in 2025, supported by the need for monitoring chronic infections and large-scale screening. ELISA remains a key technology due to its scalability in laboratories and blood banks.

Respiratory infection immunoassays are projected to expand significantly (CAGR of 10.1%), driven by rising demand for rapid diagnostics and differentiation between viral and bacterial infections, especially in point-of-care settings.

🔹 Application Insights

Diagnostic testing accounted for the largest share of 38.7% in 2025, supported by widespread use in detecting infectious diseases and evaluating overall health. Advances in technologies like CLIA, multiplexing, and biosensors are further boosting this segment.

Epidemiological surveillance is expected to grow at the highest rate (CAGR of 12.1%). Immunoassays play a vital role in tracking disease outbreaks, assessing vaccine effectiveness, and identifying immunity gaps in populations.

Infectious Disease Immunoassay Market Key Players

➢ Abbott Laboratories
➢ F. Hoffmann-La Roche Ltd .
➢ bioMérieux SA
➢ Siemens Healthineers AG
➢ Beckman Coulter, Inc.
➢ QuidelOrtho Corporation
➢ Thermo Fisher Scientific Inc.
➢ Danaher Corporation
➢ Sysmex Corporation
➢ Becton, Dickinson and Company
➢ DiaSorin S.p.A.
➢ Fujirebio Holdings, Inc.
➢ bioLytical Laboratories Inc.
➢ Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
➢ Ortho Clinical Diagnostics

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8237

Segments Covered in the Report

🔸 By Product Type

Reagents and Kits
Instruments and Analyzers
Calibrators
Controls
Software and Data Management Solutions

🔸 By Technology

Chemiluminescent Immunoassay
Enzyme-Linked Immunosorbent Assay
Fluorescent Immunoassay
Radioimmunoassay
Rapid Lateral Flow Immunoassay
Multiplex Immunoassay

🔸 By Test Type

Antigen Detection Immunoassays
Antibody Detection Immunoassays
Combined Antigen and Antibody Immunoassays
Confirmatory Immunoassays
Quantitative Immunoassays

🔸 By Disease Type

HIV Immunoassays
Hepatitis Immunoassays
Respiratory Infection Immunoassays
TORCH Infection Immunoassays
Sexually Transmitted Infection Immunoassays
Gastrointestinal Infection Immunoassays
Tropical and Vector-Borne Disease Immunoassays
Healthcare-Associated Infection Immunoassays

🔸 By Application

Screening
Diagnostic Testing
Disease Monitoring
Blood Screening
Epidemiological Surveillance

🔸 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.